AL 034
Alternative Names: AL-034; JNJ-4964; JNJ-64794964; TQ-A3334Latest Information Update: 23 Dec 2024
Price :
$50 *
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Developer Alios BioPharma; Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Antivirals; Immunotherapies
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 04 Dec 2024 Phase-II clinical trials in Hepatitis B (Combination therapy) in China (PO) (NCT06706310)
- 30 Nov 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Hepatitis B (Combination therapy) in China (PO, Tablet) (NCT06706310)
- 19 Aug 2024 Chia Tai Tianqing Pharmaceutical Group completes a phase I trial for Hepatitis B (In volunteers) in China (PO, Tablet) (NCT06160895)